Nebenwirkungen · Fingolimod Accord
Fingolimod Accord 0.5 mg hard capsules · Abschnitt 4.8 · PDF-Seite 16–17
HOS-145270 · Präparat HOS-099320
16 than 0.2% adult patients on fingolimod 0.5 mg. In the post-marketing setting, isolated reports of transient, spontaneously resolving complete AV block have been observed during the six hour monitoring period following the first dose of fingolimod. The patients recovered spontaneously. The conduction abnormalities observed both in clinical trials and post-marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation. Although most patients did not require medical intervention, one patient on fingolimod 0.5 mg received isoprenaline for asymptomatic second-degree Mobitz I atrioventricular block.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T11:08:00Z · SHA-256 c38e617848fd32f3926aeca45feca8cfb462deb5bf6268c0fe28796f89fbcbff · Passage b5f72daeb44b94dbf37a784ca4005041e1e2323db116578d5956be5a30626a7a · Zeichen 8497–9153 im Abschnitt